{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T19:21:32Z","timestamp":1790277692771,"version":"4.1.0"},"reference-count":76,"publisher":"MDPI AG","issue":"22","license":[{"start":{"date-parts":[[2021,11,10]],"date-time":"2021-11-10T00:00:00Z","timestamp":1636502400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Ascites represents a critical event in the natural history of liver cirrhosis. From a prognostic perspective, its occurrence marks the transition from the compensated to the decompensated stage of the disease, leading to an abrupt worsening of patients\u2019 life expectancy. Moreover, ascites heralds a turbulent clinical course, characterized by acute events and further complications, frequent hospitalizations, and eventually death. The pathophysiology of ascites classically relies on hemodynamic mechanisms, with effective hypovolemia as the pivotal event. Recent discoveries, however, integrated this hypothesis, proposing systemic inflammation and immune system dysregulation as key mechanisms. The mainstays of ascites treatment are represented by anti-mineralocorticoids and loop diuretics, and large volume paracentesis. When ascites reaches the stage of refractoriness, however, diuretics administration should be cautious due to the high risk of adverse events, and patients should be treated with periodic execution of paracentesis or with the placement of a trans-jugular intra-hepatic portosystemic shunt (TIPS). TIPS reduces portal hypertension, eases ascites control, and potentially modify the clinical course of the disease. Further studies are required to expand its indications and improve the management of complications. Long-term human albumin administration has been studied in two RCTs, with contradictory results, and remains a debated issue worldwide, despite a potential effectiveness both in ascites control and long-term survival. Other treatments (vaptans, vasoconstrictors, or implantable drainage systems) present some promising aspects but cannot be currently recommended outside clinical protocols or a case-by-case evaluation.<\/jats:p>","DOI":"10.3390\/jcm10225226","type":"journal-article","created":{"date-parts":[[2021,11,10]],"date-time":"2021-11-10T09:19:21Z","timestamp":1636535961000},"page":"5226","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Management of Ascites in Patients with Cirrhosis: An Update"],"prefix":"10.3390","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3219-6963","authenticated-orcid":false,"given":"Giacomo","family":"Zaccherini","sequence":"first","affiliation":[{"name":"Department of Medical and Surgical Sciences, University of Bologna, 40138 Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Tufoni","sequence":"additional","affiliation":[{"name":"IRCCS AOU di Bologna\u2014Policlinico di S. Orsola, 40138 Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Iannone","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Sciences, University of Bologna, 40138 Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Caraceni","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Sciences, University of Bologna, 40138 Bologna, Italy"},{"name":"IRCCS AOU di Bologna\u2014Policlinico di S. Orsola, 40138 Bologna, Italy"},{"name":"Center for Biomedical Applied Research, University of Bologna, 40126 Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,11,10]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.jhep.2005.10.013","article-title":"Natural history and prognostic indicators of survival in cirrhosis: A systematic review of 118 studies","volume":"44","author":"Pagliaro","year":"2006","journal-title":"J. Hepatol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.jhep.2017.10.020","article-title":"Clinical states of cirrhosis and competing risks","volume":"68","author":"Morabito","year":"2018","journal-title":"J. Hepatol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1016\/j.jhep.2015.07.004","article-title":"Mechanisms of decompensation and organ failure in cirrhosis: From peripheral arterial vasodilation to systemic inflammation hypothesis","volume":"63","author":"Bernardi","year":"2015","journal-title":"J. Hepatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.jhep.2018.03.024","article-title":"EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis","volume":"69","author":"Angeli","year":"2018","journal-title":"J. Hepatol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1002\/hep.1840080532","article-title":"Peripheral arterial vasodilation hypothesis: A proposal for the initiation of renal sodium and water retention in cirrhosis","volume":"8","author":"Schrier","year":"1988","journal-title":"Hepatology"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.jhep.2013.07.044","article-title":"Pathological bacterial translocation in liver cirrhosis","volume":"60","author":"Wiest","year":"2014","journal-title":"J. Hepatol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1053\/j.gastro.2012.09.008","article-title":"Sterile Inflammation in the Liver","volume":"143","author":"Kubes","year":"2012","journal-title":"Gastroenterology"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1053\/jhep.2003.50315","article-title":"The management of ascites in cirrhosis: Report on the consensus conference of the International Ascites Club","volume":"38","author":"Moore","year":"2003","journal-title":"Hepatology"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"215","DOI":"10.7326\/0003-4819-117-3-215","article-title":"The serum-ascites albumin gradient is superior to the exudate-transudate concept in the differential diagnosis of ascites","volume":"117","author":"Runyon","year":"1992","journal-title":"Ann. Intern. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1136\/gutjnl-2011-300779","article-title":"Spontaneous bacterial peritonitis: Recent guidelines and beyond","volume":"61","author":"Wiest","year":"2012","journal-title":"Gut"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/S0168-8278(00)80201-9","article-title":"Diagnosis, treatment and prophylaxis of spontaneous bacterial peritonitis: A consensus document. International Ascites Club","volume":"32","author":"Rimola","year":"2000","journal-title":"J. Hepatol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.jhep.2015.03.040","article-title":"Low ascitic fluid protein does not indicate an increased risk for spontaneous bacterial peritonitis in current cohorts","volume":"63","author":"Bruns","year":"2015","journal-title":"J. Hepatol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.cgh.2020.03.065","article-title":"Outcomes and mortality of grade 1 ascites and recurrent ascites in patients with cirrhosis","volume":"19","author":"Tonon","year":"2021","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1111\/j.1600-0676.1993.tb00624.x","article-title":"Efficacy and safety of the stepped care medical treatment of ascites in liver cirrhosis: A randomized controlled clinical trial comparing two diets with different sodium content","volume":"13","author":"Bernardi","year":"1993","journal-title":"Liver"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1136\/gut.19.6.549","article-title":"Advantages of treatment of ascites without sodium restriction and without complete removal of excess fluid","volume":"19","author":"Reynolds","year":"1978","journal-title":"Gut"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1111\/liv.12583","article-title":"Adherence to a moderate sodium restriction diet in outpatients with cirrhosis and ascites: A real-life cross-sectional study","volume":"35","author":"Morando","year":"2015","journal-title":"Liver Int."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1055\/s-2007-1007295","article-title":"Hepatorenal disorders: Role of the renin-angiotensin-aldosterone system","volume":"14","author":"Bernardi","year":"1994","journal-title":"Semin. Liver Dis."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1002\/hep.1840190113","article-title":"Randomized clinical study of the efficacy of amiloride and potassium canrenoate in nonazotemic cirrhotic patients with ascites","volume":"19","author":"Angeli","year":"1994","journal-title":"Hepatology"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1111\/j.1365-2362.1990.tb01800.x","article-title":"Tubular site of renal sodium retention in ascitic liver cirrhosis evaluated by lithium clearance","volume":"20","author":"Angeli","year":"1990","journal-title":"Eur. J. Clin. Investig."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1136\/gut.2008.176495","article-title":"Combined vs. sequential diuretic treatment of ascites in non-azotaemic patients with cirrhosis: Results of an open randomised clinical trial","volume":"59","author":"Angeli","year":"2010","journal-title":"Gut"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/S0168-8278(05)80217-X","article-title":"Advantages of the new loop diuretic torasemide over furosemide in patients with cirrhosis and ascites. A randomized, double blind crossover trial","volume":"17","author":"Gerbes","year":"1993","journal-title":"J. Hepatol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1016\/0016-5085(86)90249-0","article-title":"Rapid diuresis in patients with ascites from chronic liver disease: The importance of peripheral edema","volume":"90","author":"Pockros","year":"1986","journal-title":"Gastroenterology"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/j.dld.2005.07.009","article-title":"Should bleeding tendency deter abdominal paracentesis?","volume":"37","author":"Lin","year":"2005","journal-title":"Dig. Liver Dis."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1136\/gutjnl-2020-321790","article-title":"Guidelines on the management of ascites in cirrhosis","volume":"70","author":"Aithal","year":"2021","journal-title":"Gut"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1016\/0016-5085(88)90691-9","article-title":"Randomized comparative study of therapeutic paracentesis with and without intravenous albumin in cirrhosis","volume":"94","author":"Arroyo","year":"1988","journal-title":"Gastroenterology"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/S0016-5085(96)70068-9","article-title":"Randomized trial comparing albumin, dextran 70, and polygeline in cirrhotic patients with ascites treated by paracentesis","volume":"111","author":"Gines","year":"1996","journal-title":"Gastroenterology"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1053\/jhep.2003.50169","article-title":"Randomized trial comparing albumin and saline in the prevention of paracentesis-induced circulatory dysfunction in cirrhotic patients with ascites","volume":"37","author":"Minana","year":"2003","journal-title":"Hepatology"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1002\/hep.31071","article-title":"Paracentesis-Induced Circulatory Dysfunction with Modest-Volume Paracentesis Is Partly Ameliorated by Albumin Infusion in Acute-on-Chronic Liver Failure","volume":"72","author":"Arora","year":"2020","journal-title":"Hepatology"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/0016-5085(88)90441-6","article-title":"Prognostic value of arterial pressure, endogenous vasoactive systems, and renal function in cirrhotic patients admitted to the hospital for the treatment of ascites","volume":"94","author":"Llach","year":"1988","journal-title":"Gastroenterology"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1001\/archinte.1994.00420020117013","article-title":"Limitations of serum creatinine level and creatinine clearance as filtration markers in cirrhosis","volume":"154","author":"Caregaro","year":"1994","journal-title":"Arch. Intern. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1016\/j.jhep.2010.11.008","article-title":"The MELD score in patients awaiting liver transplant: Strengths and weaknesses","volume":"54","author":"Bernardi","year":"2011","journal-title":"J. Hepatol."},{"key":"ref_32","unstructured":"Biggins, S.W., Angeli, P., Garcia-Tsao, G., Gin\u00e8s, P., Ling, S., Nadim, M.K., Wong, F., and Kim, W.R. (2021). Diagnosis, evaluation, and management of ascites and hepatorenal syndrome. Hepatology."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.1111\/ajt.13408","article-title":"A Multistep, Consensus-Based Approach to Organ Allocation in Liver Transplantation: Toward a \u201cBlended Principle Model\u201d","volume":"15","author":"Cillo","year":"2015","journal-title":"Am. J. Transplant."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1002\/hep.24786","article-title":"Albumin infusion in patients undergoing large-volume paracentesis: A meta-analysis of randomized trials","volume":"55","author":"Bernardi","year":"2012","journal-title":"Hepatology"},{"key":"ref_35","first-page":"881","article-title":"Prevention of paracentesis-induced circulatory dysfunction in cirrhosis: Standard vs. half albumin doses. A prospective, randomized, unblinded pilot study","volume":"43","author":"Alessandria","year":"2011","journal-title":"Dig. Liver Dis."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.jhep.2015.05.022","article-title":"Expanding consensus in portal hypertension: Report of the Baveno VI Consensus Workshop: Stratifying risk and individualizing care for portal hypertension","volume":"63","year":"2015","journal-title":"J. Hepatol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.jhep.2016.11.001","article-title":"Beta adrenergic blockade and decompensated cirrhosis","volume":"66","author":"Reiberger","year":"2017","journal-title":"J. Hepatol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"100122","DOI":"10.1016\/j.jhepr.2020.100122","article-title":"Where does TIPS fit in the management of patients with cirrhosis?","volume":"2","author":"Saffo","year":"2020","journal-title":"JHEP Rep."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"816","DOI":"10.7326\/0003-4819-122-11-199506010-00002","article-title":"Transjugular intrahepatic portosystemic stent shunt: Effects on hemodynamics and sodium homeostasis in cirrhosis and refractory ascites","volume":"122","author":"Wong","year":"1995","journal-title":"Ann. Intern. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2738","DOI":"10.1111\/j.1572-0241.2008.02102.x","article-title":"Incidence, natural history, and risk factors of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt with polytetrafluoroethylene-covered stent grafts","volume":"103","author":"Riggio","year":"2008","journal-title":"Am. J. Gastroenterol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1016\/S0016-5085(98)70436-6","article-title":"Clinical events after transjugular intrahepatic portosystemic shunt: Correlation with hemodynamic findings","volume":"114","author":"Casado","year":"1998","journal-title":"Gastroenterology"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1148\/radiol.2017161644","article-title":"Transjugular intrahepatic portosystemic shunts in patients with cirrhosis with refractory ascites: Comparison of clinical outcomes by using 8- and 10-mm PTFE-covered stents","volume":"284","author":"Miraglia","year":"2017","journal-title":"Radiology"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1016\/j.cgh.2019.03.042","article-title":"Smaller-diameter covered transjugular intrahepatic portosystemic shunt stents are associated with increased survival","volume":"17","author":"Trebicka","year":"2019","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0168-8278(96)80065-1","article-title":"Transjugular intrahepatic portosystemic shunts: Comparison with paracentesis in patients with cirrhosis and refractory ascites: A randomized trial. French Group of Clinicians and a Group of Biologists","volume":"25","author":"Lebrec","year":"1996","journal-title":"J. Hepatol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1056\/NEJM200006083422303","article-title":"A comparison of paracentesis and transjugular intrahepatic portosystemic shunting in patients with ascites","volume":"342","author":"Ochs","year":"2000","journal-title":"N. Engl. J. Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1053\/gast.2002.37073","article-title":"Transjugular intrahepatic portosystemic shunting versus paracentesis plus albumin for refractory ascites in cirrhosis","volume":"123","author":"Uriz","year":"2002","journal-title":"Gastroenterology"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1053\/gast.2003.50088","article-title":"The North American study for the treatment of refractory ascites","volume":"124","author":"Sanyal","year":"2003","journal-title":"Gastroenterology"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1002\/hep.20364","article-title":"Randomized controlled study of TIPS versus paracentesis plus albumin in cirrhosis with severe ascites","volume":"40","author":"Salerno","year":"2004","journal-title":"Hepatology"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1007\/s00535-010-0282-9","article-title":"Transjugular intrahepatic portosystemic shunt versus paracentesis plus albumin in patients with refractory ascites who have good hepatic and renal function: A prospective randomized trial","volume":"46","author":"Narahara","year":"2011","journal-title":"J. Gastroenterol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1053\/j.gastro.2016.09.016","article-title":"Transjugular intrahepatic portosystemic shunts with covered stents increase transplant-free survival of patients with cirrhosis and recurrent ascites","volume":"152","author":"Bureau","year":"2017","journal-title":"Gastroenterology"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1136\/gutjnl-2019-318843","article-title":"Albumin in decompensated cirrhosis: New concepts and perspectives","volume":"69","author":"Bernardi","year":"2020","journal-title":"Gut"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1016\/S0140-6736(18)30840-7","article-title":"Long-term albumin administration in decompensated cirrhosis (ANSWER): An open-label randomised trial","volume":"391","author":"Caraceni","year":"2018","journal-title":"Lancet"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1111\/liv.13968","article-title":"Long-term administration of human albumin improves survival in patients with cirrhosis and refractory ascites","volume":"39","author":"Fasolato","year":"2019","journal-title":"Liver Int."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1016\/j.jhep.2018.08.006","article-title":"Midodrine and albumin for prevention of complications in patients with cirrhosis awaiting liver transplantation. A randomized placebo-controlled trial","volume":"69","author":"Castellote","year":"2018","journal-title":"J. Hepatol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"S201","DOI":"10.21037\/atm.2019.07.16","article-title":"Prolonged albumin administration in patients with decompensated cirrhosis: The amount makes the difference","volume":"7","author":"Tufoni","year":"2019","journal-title":"Ann. Transl. Med."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.jhep.2020.08.021","article-title":"On-treatment serum albumin level as guide for long-term albumin treatment of patients with cirrhosis and uncomplicated ascites","volume":"74","author":"Caraceni","year":"2021","journal-title":"J. Hepatol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"M18","DOI":"10.1093\/geronj\/43.1.M18","article-title":"The effect of age on serum albumin in healthy males: Report from the Normative Aging Study","volume":"43","author":"Campion","year":"1988","journal-title":"J. Gerontol."},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Italian Association for the Study of the Liver (AISF) (2021). Portal Hypertension and Ascites: Patient- and Population-centered Clinical Practice Guidelines by the Italian Association for the Study of the Liver (AISF). Dig. Liver Dis., 53, 1089\u20131104.","DOI":"10.1016\/j.dld.2021.06.021"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1016\/S0140-6736(08)60695-9","article-title":"Non-peptide arginine-vasopressin antagonists: The vaptans","volume":"371","author":"Decaux","year":"2008","journal-title":"Lancet"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1111\/apt.12025","article-title":"Meta-analysis: The safety and efficacy of vaptans (tolvaptan, satavaptan and lixivaptan) in cirrhosis with ascites or hyponatraemia","volume":"36","author":"Dahl","year":"2012","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Yan, L., Xie, F., Lu, J., Ni, Q., Shi, C., Tang, C.-X., and Yang, J. (2015). The treatment of vasopressin V2-receptor antagonists in cirrhosis patients with ascites: A meta-analysis of randomized controlled trials. BMC Gastroenterol., 15.","DOI":"10.1186\/s12876-015-0297-z"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.amjmed.2016.09.011","article-title":"Limited Efficacy of Tolvaptan in Patients with Cirrhosis and Severe Hyponatremia: Real-Life Experience","volume":"130","author":"Pose","year":"2017","journal-title":"Am. J. Med."},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Hosui, A., Tanimoto, T., Okahara, T., Ashida, M., Ohnishi, K., Wakahara, Y., Kusumoto, Y., Yamaguchi, T., Sueyoshi, Y., and Hirao, M. (2021). Early Administration of Tolvaptan Can Improve Survival in Patients with Cirrhotic Ascites. J. Clin. Med., 10.","DOI":"10.3390\/jcm10020294"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1056\/NEJMoa1205511","article-title":"Tolvaptan in patients with autosomal dominant polycystic kidney disease","volume":"367","author":"Torres","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1007\/s00134-014-3210-2","article-title":"Clinical practice guideline on diagnosis and treatment of hyponatraemia","volume":"40","author":"Spasovski","year":"2014","journal-title":"Intensive Care Med."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.jhep.2006.09.012","article-title":"Effects of a 7-day treatment with midodrine in non-azotemic cirrhotic patients with and without ascites","volume":"46","author":"Kalambokis","year":"2007","journal-title":"J. Hepatol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.jhep.2011.04.027","article-title":"Midodrine in patients with cirrhosis and refractory or recurrent ascites: A randomized pilot study","volume":"56","author":"Singh","year":"2012","journal-title":"J. Hepatol."},{"key":"ref_68","first-page":"1915","article-title":"Clinical study on the therapeutic role of midodrine in non azotemic cirrhotic patients with tense ascites: A double-blind, placebo-controlled, randomized trial","volume":"61","author":"Ali","year":"2014","journal-title":"Hepatogastroenterology"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1002\/hep.21355","article-title":"Effects of clonidine on diuretic response in ascitic patients with cirrhosis and activation of sympathetic nervous system","volume":"44","author":"Lenaerts","year":"2006","journal-title":"Hepatology"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1038\/ajg.2013.9","article-title":"Midodrine and clonidine in patients with cirrhosis and refractory or recurrent ascites: A randomized pilot study","volume":"108","author":"Singh","year":"2013","journal-title":"Am. J. Gastroenterol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/j.jhep.2012.12.020","article-title":"Automated low flow pump system for the treatment of refractory ascites: A multi-center safety and efficacy study","volume":"58","author":"Bellot","year":"2013","journal-title":"J. Hepatol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/j.jhep.2017.06.010","article-title":"Alfapump\u00ae system vs. large volume paracentesis for refractory ascites: A multicenter randomized controlled study","volume":"67","author":"Bureau","year":"2017","journal-title":"J. Hepatol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1111\/apt.15502","article-title":"Systematic review with meta-analysis: Automated low-flow ascites pump therapy for refractory ascites","volume":"50","author":"Lepida","year":"2019","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1002\/lt.24763","article-title":"Effects of alfapump system on kidney and circulatory function in patients with cirrhosis and refractory ascites","volume":"23","author":"Rodriguez","year":"2017","journal-title":"Liver Transpl."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1038\/s41575-018-0045-2","article-title":"Novel perspectives in the management of decompensated cirrhosis","volume":"15","author":"Bernardi","year":"2018","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"S118","DOI":"10.1016\/j.jhep.2021.01.024","article-title":"The search for disease-modifying agents in decompensated cirrhosis: From drug repurposing to drug discovery","volume":"75","author":"Caraceni","year":"2021","journal-title":"J. Hepatol."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/10\/22\/5226\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:28:28Z","timestamp":1760167708000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/10\/22\/5226"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,10]]},"references-count":76,"journal-issue":{"issue":"22","published-online":{"date-parts":[[2021,11]]}},"alternative-id":["jcm10225226"],"URL":"https:\/\/doi.org\/10.3390\/jcm10225226","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,10]]}}}